Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression

M Baboudjian, A Breda, P Rajwa, A Gallioli… - European Urology …, 2022 - Elsevier
Context Active surveillance (AS) is increasingly selected among patients with localized,
intermediate-risk (IR) prostate cancer (PCa). However, the safety and optimal candidate …

Entecavir: A Review and Considerations for Its Application in Oncology

T Lourenço, N Vale - Pharmaceuticals, 2023 - mdpi.com
Entecavir (ETV) is a drug used as a first-line treatment for chronic hepatitis B (CHB) virus
infection because it is a guanosine nucleoside analogue with activity against the hepatitis B …

[HTML][HTML] Increasing aggressive prostate cancer

N Shah, V Ioffe, JC Chang - The Canadian journal of urology, 2022 - ncbi.nlm.nih.gov
Materials and methods: We completed a retrospective comparative analysis of 1703
sequential patients that had a Pbx in 2010 to 2012 (3 years) with 1006 patients biopsied in …

Comparison of outcomes of active surveillance in intermediate-risk versus low-risk localised prostate cancer patients: A systematic review and meta-analysis

S Mukherjee, D Papadopoulos, JM Norris… - Journal of Clinical …, 2023 - mdpi.com
Currently, there is no clear consensus regarding the role of active surveillance (AS) in the
management of intermediate-risk prostate cancer (IRPC) patients. We aim to analyse data …

Theranostic Robot-Assisted Radical Prostatectomy: Things Understood and Not Understood

CY Hsu, CH Yang, MC Tung, HJ Liu, YC Ou - Cancers, 2023 - mdpi.com
Simple Summary Theranostic robot-assisted radical prostatectomy (T-RARP) means
adopting RARP as an integration of diagnosis and therapy, and this concept has rarely been …

[HTML][HTML] Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic …

BA Gartrell, A Phalguni, P Bajko, SD Mundle… - European Urology …, 2024 - Elsevier
Context Treatment decision-making (TDM) for patients with localized (LPC) or locally
advanced (LAPC) prostate cancer is complex, and post-treatment decision regret (DR) is …

Testosterone therapy and prostate cancer: incorporating low-level evidence into practical recommendations

A Morales, DR Siemens - Urologic Clinics, 2022 - urologic.theclinics.com
In men's health 2 fields share the characteristics of being both controversial and involving
several medical disciplines: testosterone deficiency syndrome (TDS) and prostate cancer …

The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer

NM Posielski, S Shanmuga, O Ho, J Jiang… - Prostate cancer and …, 2023 - nature.com
Abstract Introduction Racial differences in Health-Related Quality of Life (HRQoL) after
treatment of prostate cancer (PCa) are not well studied. We compared treatment patterns …

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer

G Gandaglia, R Leni, S Plagakis, A Stabile, F Montorsi… - BMC urology, 2023 - Springer
Active surveillance has been proposed as a therapeutic option in selected intermediate risk
patients with biopsy grade group 2 prostate cancer. However, its oncologic safety in this …

Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data

C Dariane, F Chierigo, V Ouellet, N Delvoye… - The French Journal of …, 2024 - Elsevier
Introduction Active surveillance (AS) has emerged as a primary management strategy for
low-risk prostate cancer (PC) patients. We aimed to assess AS uptake over a 1-year …